Advanced Filters
noise
Found 1,873 clinical trials
F Francisco Cartujano, MD

Advancing Lung Cancer Screening One Text at a Time

The purpose of this study is to assess the feasibility, acceptability, and preliminary impact of text messaging to promote lung cancer screening.

50 - 80 years of age All Phase N/A
W Wu yilong, phD

SKB500 Combinations in Patients With Small Cell Lung Cancer

The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.

18 - 75 years of age All Phase 2
R Raquel Sebio

Concomitant Use of Radiotherapy and Integrated Exercise - Lung Cancer

Study objective and procedures The objective of CURIE-LC is to evaluate the feasibility (i.e., whether it is possible and safe) of carrying out a comprehensive exercise program during combined radiotherapy and chemotherapy in patients with lung cancer. The study will assess whether patients can adhere to the exercise program while …

18 years of age All Phase N/A

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

years of age All Phase 1
A Alexandria Grindlay

Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)

It is reported that more than 90,000 patients died of lung cancer and more than 20% of them were older than 80 years in North America. Therefore a less invasive but effective treatment is required for patients with lung cancer of advanced age, diminished pulmonary functions, and chronic diseases. Stereotactic …

18 years of age All Phase N/A

Molecular Signature From Tumor to Lymph Nodes

Mediastinal lymph node (LN) involvement (N2) in non-small cell lung cancer (NSCLC) concerns 15% of resectable tumors and is associated with a poor prognosis and an overall survival reaching 9 to 49%. Literature fails to provide any definitive consensus regarding the management of these patients, except for the platinum-based doublet …

18 years of age All Phase N/A
L Line Larsen

Navigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients

Half of patients with lung cancer face a limited life span of one-year survival, which is characterized by severe physical and psychological symptoms. Differences in stage, comorbidity but also treatment may explain a large proportion of the social inequality in lung cancer survival. Some vulnerable patients may not receive first …

18 years of age All Phase N/A
C Charles Kambourakis

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to …

18 years of age All Phase 2

Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer

The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI. The further analysis of …

18 years of age All Phase N/A
G Georg-Christian Funk, MD

LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice

This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung …

18 - 125 years of age All Phase N/A

Simplify language using AI